Exelixis (MIL:1EXEL) Accounts Payable: €34 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1EXEL Exelixis Inc MIL:1EXEL
74 GF Score
Price €45.90
GF Value €40.82
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Exelixis Accounts Payable?

Exelixis MIL:1EXEL 74 Accounts Payable is €34 Mil as of Jun. 2026. GuruFocus rates MIL:1EXEL with a GF Score™ of 74/100 and a GF Value™ of €40.82 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Exelixis's Accounts Payable for the quarter that ended in Jun. 2026 was €34 Mil.

Exelixis's quarterly Accounts Payable declined from Dec. 2025 (€25 Mil) to Mar. 2026 (€21 Mil) but then increased from Mar. 2026 (€21 Mil) to Jun. 2026 (€34 Mil).

Exelixis's annual Accounts Payable increased from Dec. 2023 (€31 Mil) to Dec. 2024 (€36 Mil) but then declined from Dec. 2024 (€36 Mil) to Dec. 2025 (€25 Mil).

Exelixis Accounts Payable Historical Data

* Premium members only.

The historical data trend for Exelixis's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exelixis Accounts Payable Chart

Exelixis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.47 30.84 30.97 36.47 25.30

Exelixis Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.39 21.60 25.30 20.89 33.91
MIL:1EXEL
74GF Score
Exelixis Inc MIL:1EXEL
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Exelixis Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €34 Mil mean?
Exelixis (MIL:1EXEL) has a Accounts Payable of €34 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Exelixis and its competitors.
Is Exelixis' Accounts Payable too high?
Exelixis' current Accounts Payable is €34 Mil. Overall, Exelixis has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Exelixis' Accounts Payable compare to MDGL and AXSM?
Exelixis' Accounts Payable of €34 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Exelixis and its competitors. Exelixis's current Accounts Payable is €34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exelixis stock overvalued right now?
Based on GuruFocus' analysis, Exelixis (MIL:1EXEL) is currently considered Modestly Overvalued. The stock's GF Value™ is €40.82, compared to a current price of €45.90 — trading 12.4% above its estimated fair value. The current Accounts Payable is €34 Mil. Exelixis' overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Exelixis (MIL:1EXEL), the current Accounts Payable is €34 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Exelixis (MIL:1EXEL) Overvalued in 2026?

Based on GuruFocus' analysis, Exelixis stock appears to be overvalued. The current stock price of €45.90 is trading 12.4% above its estimated GF Value™ of €40.82. GuruFocus considers Exelixis to be Modestly Overvalued.

Key valuation signals for MIL:1EXEL:

  • Accounts Payable: €34 Mil
  • GF Value™: €40.82 vs. price of €45.90 (12.4% above fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the MIL:1EXEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Exelixis Business Description

Address 1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
74GF Score

Get the complete analysis for MIL:1EXEL

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€45.90
Price
€40.82
GF Value